In this final long-term analysis of the groundbreaking MURANO trial, progression-free survival (PFS) and overall survival (OS) benefits for venetoclax-rituximab (VenR) over bendamustine-rituximab (BR) were once again confirmed.
Before deciding on the best therapy choice to treat my CLL / SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma), I first needed to determine if it was the right time to start therapy.
Patients diagnosed with blood cancers are at higher risk of developing second cancers, especially second blood cancers.
A newly published paper in the New England Journal of Medicine found that pirtobrutinib shows efficacy in patients with heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had received a covalent Bruton tyrosine kinase inhibitor (BTKi).
Pirtobrutinib is a new BTK inhibitor that binds differently (non-covalently) to BTK than the three approved BTK inhibitors, ibrutinib, acalabrutinib, and zanubrutinib.
Bruton tyrosine kinase (BTK) degraders are a new therapeutic area that might be able to overcome mutations that cause resistance to BTK inhibitors.
Acalabrutinib produced durable responses in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at higher risk of disease progression.
Shorter telomere lengths was found in Americans of African ancestry with CLL compared to those with European ancestry
Follow-up results from a phase 1/2 trial of acalabrutinib in CLL / SLL patients further confirm that acalabrutinib is safe & effective.
